EXPLAINED: Is biogen stock underperforming the dow - The Real Truth

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $28.8 billion, the company’s products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and BIIB perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the general drug manufacturers industry. BIIB solidifies its leadership in neurology and specialized immunology through its innovative and diversified product portfolio. Flagship multiple sclerosis treatments, TECFIDERA and AVONEX, maintain market dominance. The strategic acquisition of Reata expands BIIB's footprint into rare diseases with SKYCLARYS, the pioneering treatment for Friedreich's Ataxia, further bolsters its competitive position.